Hepatocellular carcinoma

This trial is testing a high-dose radiation treatment called Yttrium-90 radioembolization for people with large hepatocellular carcinoma (a type of liver cancer) that is larger than 8 cm. The treatment delivers tiny radioactive beads directly to the tumor's blood supply, aiming t…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

Researchers test whether irreversible electroporation, a technique that uses electrical pulses to destroy tumor cells while sparing nearby blood vessels and bile ducts, can boost the effects of lenvatinib and sintilimab in people with advanced hepatocellular carcinoma that cannot…

This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…

This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor…

This trial tests whether adding daily oral zinc to standard targeted therapy and immunotherapy helps people with advanced liver cancer. About 60 participants will be randomly assigned to receive the standard treatment alone or with either 20 mg or 30 mg of zinc each day. The main…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

Researchers are testing whether combining microwave ablation with infusions of a patient's own expanded immune cells helps people with small liver tumors. The trial enrolls adults with up to three tumors, each no larger than 5 cm, who are not eligible for surgery. After ablation,…

Researchers are testing whether adding two immunotherapy drugs, durvalumab and tremelimumab, to focused radiation before surgery changes the immune cell makeup inside liver tumors. The trial enrolls 30 people with a single liver tumor that can be removed surgically. Everyone rece…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This phase 2 trial is testing whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with lenvatinib, radiotherapy, and chemotherapy delivered directly to the liver can help people with hepatocellular carcinoma that has spread into the portal vein. The study aim…

This study is testing whether memantine, a drug currently used for Alzheimer's disease, can help slow the growth of liver cancer in people with advanced cirrhosis. The trial will enroll 12 adults with liver cancer that cannot be removed by surgery and who are not candidates for s…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

This study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…

This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the best dose and see if the combination can shrink tumors. Participants must…

Researchers are testing whether adding oral fecal microbiota transplantation capsules can help control advanced hepatocellular carcinoma that has worsened during treatment with immune checkpoint inhibitors and tyrosine kinase inhibitors. The trial enrolls 30 adults with liver can…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This phase II trial tests whether combining anlotinib, benmelstobart, and hepatic arterial infusion chemotherapy (HAIC) can shrink tumors in people with unresectable hepatocellular carcinoma, the most common type of liver cancer. The study enrolls adults aged 18 to 75 with confir…

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This phase 2 trial tests whether a single injection of IP-001, given right after standard liver cancer ablation or surgery plus ablation, can help keep the cancer from coming back. About 126 adults with intermediate to high risk of recurrence will be followed for at least two yea…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This phase 2 trial tests whether combining an immunotherapy drug (iparomlimab/tuvonralimab), targeted radiation, and the drug lenvatinib can improve outcomes for people with intermediate-stage liver cancer that may be removable by surgery. Participants receive the combination bef…

This large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…

This study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if…

This trial tests whether adding a procedure called irreversible electroporation (IRE) to standard targeted immunotherapy can help people with unresectable liver cancer that has spread into the portal vein. About 60 adults who have already received three cycles of immunotherapy wi…

This Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …

This phase 3 trial compares two treatments for small liver cancer (tumors 5 cm or smaller): surgery to remove the tumor or a precise, high-dose radiation therapy called SBRT. About 312 adults with a single liver tumor will be randomly assigned to one of the two treatments. The st…

This trial tests whether adding an experimental drug called valemetostat to a standard two-drug therapy can help people with advanced liver cancer. The standard therapy combines atezolizumab and bevacizumab, which are already approved for this condition. The study includes adults…

This trial tests whether giving patients their own activated T lymphocytes (ATL) after curative treatment for liver cancer can reduce the chance of the cancer coming back. The study enrolls adults with stage I, II, or IIIa hepatocellular carcinoma who have had or will have curati…

This early-phase study tests a new experimental drug (BRII-5395) combined with two approved cancer treatments (sintilimab and bevacizumab) in about 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while …

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This trial tests an inhaled biologic called YSCH-01 in people with advanced non-small cell lung cancer or advanced solid tumors that have spread to the lungs. The study aims to find the safest dose and see if the treatment can shrink tumors or slow the disease. Participants inhal…

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This phase 2 trial tests whether a powerful mix of liver-directed chemotherapy, a targeted drug (lenvatinib), and an immunotherapy (cadonilimab) can shrink liver cancers that were too large or widespread to remove. The goal is to convert these inoperable tumors into ones that can…

This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects.…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This trial investigates whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can control advanced liver cancer in patients with moderate cirrhosis (Child-Pugh B). The dosing is adjusted based on how each patient responds. The study aims to see how many pati…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This trial is testing a procedure called ablative radioembolization, which delivers tiny radioactive beads (Yttrium-90) directly to liver tumors. It is for adults with hepatocellular carcinoma that has spread into the portal vein but is still confined to one lobe of the liver. Th…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…

This trial tests a targeted radiation therapy for people with large, localized liver cancer that cannot be surgically removed. Tiny glass beads carrying Yttrium-90 are injected into the liver's blood vessels to deliver a high dose of radiation directly to tumors. Researchers will…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This study tests whether adding pegylated interferon alpha-2b to standard targeted immunotherapy can help people with advanced liver cancer caused by hepatitis B. The trial enrolls adults with unresectable, intermediate-to-advanced disease who are already on antiviral therapy. Pa…

This study tests whether people with large liver cancer (over 5 cm) can get their entire radioembolization treatment in a single day. Normally, planning scans and treatment are done on separate days. The procedure involves injecting tiny radioactive beads into the liver's blood s…

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…

This study tests a faster version of radioembolization for people with small liver cancers (5 cm or less). Normally, doctors do a pre-treatment scan to check for lung risks, but this trial skips that step for carefully selected patients. The goal is to see if the simplified appro…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This early-stage trial is testing an experimental vaccine called YMN-136 in people with advanced liver, pancreatic, or biliary tract cancer that has progressed after standard treatment. The main goal is to check the vaccine's safety and find the best dose, while also seeing if it…

This early study tests a PD-1 mRNA vaccine in 9 adults with advanced liver cancer that has not responded to standard treatments. The vaccine is given as weekly shots for four weeks, then a fifth shot a month later. The main goal is to check safety, but researchers will also see i…

This study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…

This trial tests whether a personalized nutrition plan, combined with exercise and psychological support before surgery, can improve outcomes for people with primary liver cancer. Participants are randomly assigned to receive either standard dietary advice or an enhanced program …

This phase 2 trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) works better than STRIDE alone for people with advanced liver cancer that cannot be surgically removed. About 140 adults who have not had prior systemic therapy will be enrolle…

This trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 pa…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This early-stage trial is testing a new drug called FS-8002, alone or combined with other treatments, in 66 people with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and get a first look at whether th…

This phase II trial tests whether adding the immunotherapy drug atezolizumab to a targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. The study enrolls 122 adults whose…

This phase II trial tests whether combining a liver-directed procedure (TACE) with an immunotherapy drug (QL1706) before surgery, followed by more immunotherapy after surgery, can help patients with liver cancer that is too large or numerous for standard transplant criteria. The …

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This phase 2 trial tests a personalized dendritic cell vaccine combined with the immunotherapy drug nivolumab in 60 people who had surgery for liver cancer or colorectal cancer that spread to the liver. The vaccine is made from each patient's unique tumor mutations and aims to tr…

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…

This early-phase trial tests a new drug called MRG006A, combined with immunotherapy and targeted therapy, in 160 people with advanced hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery. The study aims to check safety, find the right dose, and se…

This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y-90) can shrink liver tumors enough for patients to become eligible for a liver transplant. About 40 adults with hepatocellular carcinoma (HCC) will receive this combin…

This study tests a new drug (CVM-1118) combined with an immunotherapy (sintilimab) and a procedure that blocks the tumor's blood supply (TACE) in people with liver cancer that cannot be cured but hasn't spread. About 40 adults will receive all three treatments to see if the combi…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This study is testing whether applying a radiofrequency device to the cut surface of the liver after tumor removal can reduce the chance of cancer returning at that spot. About 720 adults with liver cancer (either colorectal metastases or hepatocellular carcinoma) will be randoml…

This phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study…

This study looks at whether adding lidocaine to standard sedation during radiofrequency ablation for liver cancer can reduce inflammation and lower the chance of the cancer returning. The researchers focus on a process called NETosis, which is linked to tumor growth and spread. O…

This study tests whether combining an immunotherapy drug (camrelizumab), a targeted therapy (rivoceranib), and liver-directed chemotherapy (HAIC) can shrink intermediate-to-advanced liver tumors enough to allow surgical removal. About 400 adults with potentially resectable hepato…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests a new drug, Irpagratinib, added to two standard drugs (Atezolizumab and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and shrinks tumors. About 33 adults with a specific genetic…

This trial tests whether an experimental drug called FB-1603 can protect liver function in people with liver cancer who are receiving a standard procedure called transarterial chemoembolization (TACE). Participants take either a low dose, a high dose, or a placebo capsule daily f…

This phase 2 trial is testing whether an artificial intelligence system can find the best doses of three drugs (irinotecan, sonidegib, and sorafenib) for people with advanced liver cancer. The study will enroll 12 adults whose cancer has not responded to other treatments. The goa…

This trial tests a treatment for people with liver cancer that cannot be removed by surgery. Tiny beads called BioPearl microspheres are loaded with the chemotherapy drug doxorubicin and injected into the blood vessels feeding the tumor. The beads block blood flow and release the…

This study tests whether combining two drugs, atezolizumab and bevacizumab, given before and after surgery can help prevent liver cancer from coming back. It enrolls adults with a type of liver cancer that can be surgically removed but has a high risk of recurrence. Participants …

This trial investigates a new cell therapy called ET140203 T cells for children and young adults (ages 1–21) with certain liver cancers—hepatoblastoma, hepatocellular carcinoma, or related tumors—that have come back or not responded to standard treatment. Participants must have h…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This study tests a new way to treat advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with a blood vessel blocker (bevacizumab) and standard chemotherapy, all given directly into the liver's main artery or through a vein. The goal is to see if…

This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for…

This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its s…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This study tests a drug called zanzalintinib in people with advanced liver cancer that has spread or cannot be cured. The trial has two parts: first, finding the safest dose, then checking if it helps control the cancer. About 59 participants will take the drug by mouth, and rese…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This study tests whether combining procedures that block blood flow to liver tumors (TACE or HAIC) with targeted drugs and immunotherapy can help control advanced hepatocellular carcinoma that cannot be surgically removed. The trial enrolls adults aged 18–80 with large or vein-in…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This study tests a new drug called HH-009 in people with advanced liver cancer that has worsened after other treatments. About 30 participants will receive one of two doses to see if it can slow or stop cancer growth. The goal is to find out if the drug is safe and effective.

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests a new drug called BL-B01D1, alone or with other cancer drugs, in 74 people with advanced liver cancer that has spread. The goal is to see if these combinations can shrink tumors and how safe they are. Participants will receive the drugs through an IV or as pills …

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study compares a precise radiation technique called SABR against standard treatments (like heat probes or chemo injections) for early-stage liver cancer. About 218 adults with a single tumor up to 8 cm will be randomly assigned to SABR or standard care. The main goal is to s…

This study tests whether a fecal microbiota transplant (FMT) can help liver cancer patients who stopped responding to standard drugs. Fifteen adults with advanced liver cancer will receive FMT along with atezolizumab and bevacizumab to see if the combination can restore tumor con…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track ho…

This study tests a combination of three drugs—chemotherapy infused directly into the liver, a targeted pill, and an immunotherapy—in 38 people with advanced liver cancer that has spread into the main portal vein. The goal is to shrink the tumor enough so that surgeons can remove …

This study is for adults with advanced liver cancer (hepatocellular carcinoma) that is hard to treat. It compares two standard drug regimens — immunotherapy (atezolizumab + bevacizumab) or targeted pills (lenvatinib or cabozantinib) — given after a liver-directed radiation treatm…

This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib helps shrink tumors or slow cancer growth in people with advanced liver cancer. About 80 adults whose cancer worsened after initial immunotherapy will be randomly assigned to receive eit…

This Phase 3 trial tests whether a chemotherapy infusion directly into the liver (HAIC) plus immunotherapy drugs works better than the standard chemo-embolization procedure (TACE) plus the same immunotherapy for people with intermediate-stage liver cancer that has spread extensiv…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tissue. …

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This study looks at whether adding focused radiation to spots where cancer is growing can help people with advanced liver cancer whose first immunotherapy treatment has partly stopped working. About 30 adults with limited new growth will receive radiation to those spots while con…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This early-phase trial is testing a new treatment called Super CAR-T for people with advanced hepatocellular carcinoma, a type of liver cancer that has spread. The treatment involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, …

This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will …

This clinical trial is testing a new drug called VRT106 combined with two other drugs (camrelizumab and apatinib) in people with advanced liver cancer that has not responded to prior immunotherapy. The study will enroll 66 participants and aims to see if the combination is safe a…

This study tests a powerful combination of treatments for people with advanced liver cancer that cannot be surgically removed. The approach uses heat-based ablation to destroy the main tumor, followed by targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a procedure…

This study tests whether adding a precise, high-dose radiation treatment (SBRT) after a standard procedure (TACE) can better control liver cancer in people whose tumors cannot be surgically removed. About 30 adults with early- or intermediate-stage liver cancer will receive the c…

This trial tests whether a computer guidance software can help doctors more completely destroy liver tumors during microwave ablation. About 84 adults with liver cancer (HCC) will have the procedure with the software's assistance, and their outcomes will be compared to historical…

This study tests a combination of two drugs—tislelizumab (an immunotherapy) and huaier granule (a traditional Chinese medicine)—as a first treatment for people with advanced liver cancer that cannot be surgically removed. About 94 adults will receive this combination to see if it…

This study tests whether a drug called polyene phosphatidylcholine, given before and after surgery, can protect the liver in people with liver cancer. About 96 participants will receive either the drug combo or standard care. The goal is to see if it reduces liver injury after la…

This early-stage trial is testing a new drug called ZW251 in about 100 people with advanced solid tumors, including liver cancer (hepatocellular carcinoma), a type of lung cancer (squamous cell non-small cell lung cancer), and germ cell tumors. ZW251 is an antibody-drug conjugate…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a two-step treatment for people with advanced liver cancer that has spread into the main liver blood vessel (portal vein). First, patients receive targeted radiation (SIRT) to shrink the tumor from inside the liver. Then, they get two immunotherapy drugs (durvalu…

This study tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard two-drug combos for people with advanced liver cancer that cannot be removed by surgery. About 590 adults who have not had prior cancer treatment will participate. The …

This phase 2 trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can improve outcomes for people with liver cancer at high risk of recurrence. About 33 participants will receive the…

This phase 3 trial tests whether drug-eluting bead chemoembolization (DEB-TACE) works better than conventional chemoembolization (cTACE) for liver cancer patients who have had a TIPS procedure to manage complications of cirrhosis. The study will enroll 206 participants and track …

This phase II trial tests a combination of four treatments—two immunotherapies (ipilimumab N01 and sintilimab), a targeted therapy (bevacizumab biosimilar), and chemotherapy directly into the liver—for people with advanced liver cancer that cannot be surgically removed. The goal …

This early-stage trial tests a new drug called SHR-2524 combined with bevacizumab in 36 people with advanced liver cancer that hasn't been treated before. The main goals are to check safety, how the body processes the drugs, and to get an early look at whether the combination mig…

This pilot study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) and focused radiation before surgery in 15 people with advanced liver cancer that is borderline removable. The goal is to see if this approach is safe and can shrink tumors enough to allow …

This study compares two treatments for advanced liver cancer (BCLC stage C): standard drug therapy alone versus drug therapy plus a precise type of radiation called stereotactic body radiotherapy (SBRT). The goal is to see if adding radiation helps people live longer. About 184 a…

This study tests a new oral drug called TTI-101 in people with advanced liver cancer that cannot be removed by surgery. The drug is given alone or combined with standard immunotherapy drugs. The main goals are to check safety and see if the drug shrinks tumors. About 193 adults w…

This study tests a combination of a standard liver cancer procedure (TACE) with three immunotherapy drugs (sintilimab, bevacizumab, and ipilimumab) in 36 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if this mix is safe and works better t…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This Phase 2 trial tests whether adding an experimental drug called RBS2418 to a standard immunotherapy regimen (tremelimumab plus durvalumab) can better control advanced liver cancer that cannot be removed by surgery. About 220 adults will receive either the combination or the s…

This Phase 2 trial is testing whether adding a targeted chemotherapy infusion into the liver (HAIC) to a combination of two drugs—sintilimab (an immunotherapy) and bevacizumab biosimilar (which blocks blood vessel growth)—helps people with advanced liver cancer live longer withou…

This study tests several new drug combinations for people with advanced liver cancer whose first treatment stopped working. It involves 350 adults and uses advanced imaging and genetic tests to find which treatment works best for each person. The goal is to shrink or control the …

This study is observing 150 adults with advanced liver cancer who are starting immunotherapy for the first time. Researchers will track how well different drug combinations shrink tumors and how the immune system changes. The goal is to learn which treatments work best and why, w…

This study tests a drug called Becotatug vedotin in 40 adults with advanced liver cancer that has worsened after standard treatments. The goal is to see if it can shrink tumors and help control the disease. Participants receive the drug and are monitored for safety and response.

This early-phase trial tests a drug called tirapazamine, which becomes active only in low-oxygen (hypoxic) areas of tumors, combined with a standard procedure that blocks blood flow to the tumor (transarterial embolization). The goal is to find the best dose and see if the combin…

This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure c…

This study tests whether adding a drug that blocks a cancer cell survival process called autophagy can make standard TACE therapy more effective for liver cancer. TACE cuts off the tumor's blood supply, but cancer cells often survive by eating their own parts for energy. The tria…

This study tests a combination of two drugs, IBI310 and sintilimab, as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 680 participants will receive either the combination or standard care. The goal is to see if the combination shr…

This phase 3 trial is testing whether adding two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. The study will enroll 101 participants wi…

This study compares two types of radiation therapy for people with liver cancer (hepatocellular carcinoma). One method delivers radiation directly to the tumor through a small tube in an artery, while the other uses a precise external beam. The goal is to see which approach bette…

This study tests a new method to check if a liver cancer treatment called radioembolization is safe for the lungs. Currently, doctors use a test particle (MAA) to estimate lung radiation risk, but it may not be perfectly accurate. The new method uses a small 'scout dose' of the a…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This study tests two new drugs: one to help spot liver cancer cells (RYZ811) and another to deliver treatment directly to them (RYZ801). It is for people with a type of liver cancer called GPC3-positive hepatocellular carcinoma that cannot be removed by surgery. The goal is to se…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests a device called TheraBionic P1 in people with advanced liver cancer who have already tried at least two other treatments or cannot take standard therapy. The goal is to see if the device can help them live longer and improve their quality of life. About 198 adult…

This study is testing a new microwave ablation device to treat small liver cancers (up to 4 cm). Doctors will use ultrasound guidance to insert a thin antenna into the tumor and apply microwave energy to heat and destroy it. The goal is to see how often the tumor is completely el…

This study tests a new drug called CVM-1118 combined with an immunotherapy drug (nivolumab) in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will take part to see if the combination shrinks tumors and how long any benefit lasts. The goal is …

This clinical trial compares two types of radiation therapy—SBRT and SIRT—each combined with immunotherapy, for people with advanced liver cancer that cannot be removed by surgery. About 106 participants will be randomly assigned to one of the two treatments. The goal is to see w…

This early-stage trial tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study includes 38 adults with advanced solid tumors, such as liver cancer, who have not responde…

This study is for people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. It compares two second-line approaches: adding lenvatinib to the original regimen or switching to regorafenib plus a PD-1 inhibitor. The goal is to see which c…

This study tests a new treatment for adults with advanced liver cancer that cannot be removed by surgery or has spread. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins found on liver cancer cells. Participa…

This study tests whether a short infusion of angiotensin II, given directly into the liver artery, can help radioactive beads reach liver tumors more effectively while sparing healthy tissue. About 15 adults with liver cancer will receive the drug right before standard radioembol…

This study tests a personalized mRNA vaccine (iNeo-Vac-R01) made from each patient's tumor, combined with an immunotherapy drug (PD-1 inhibitor), to prevent liver cancer from coming back after surgery. About 20 adults with early-stage liver cancer will receive the treatment. The …

This study tests whether two drugs, sintilimab and bevacizumab, given after surgery can prevent cancer from coming back in people with ruptured liver cancer. About 35 participants will receive the combination every three weeks. The goal is to see if this approach is safe and impr…

This early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a protein called GPC3. The main goal is to check the drug's safety and find the right dose. Researchers will also measure how the drug moves through the body and look fo…

This study is testing whether combining immunotherapy drugs (tremelimumab and durvalumab) with liver-directed procedures like TACE, TARE, or RFA can shrink liver cancer enough to make patients eligible for a liver transplant. The trial enrolls 41 adults with hepatocellular carcin…

This study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…

This early-stage trial tests an investigational drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular carcinoma) or a type of lung cancer (squamous-cell non-small cell lung cancer). Some participants receive ABBV-324 alone, while others get a standard drug ca…

This phase 2 trial is testing whether adding proton radiotherapy to standard immunotherapy (atezolizumab and bevacizumab) can better control advanced liver cancer that cannot be removed by surgery. About 45 participants will receive the combination treatment. The study will measu…

This study tests a combination of internal radiation (Y90-SIRT) with three drugs (nivolumab, ipilimumab, and lenvatinib) in 33 people with liver cancer that cannot be surgically removed. The goal is to see if this powerful mix is safe and can shrink tumors or extend survival. It …

This study tests a newer, ultrasound-guided endoscopic technique to prevent repeat bleeding from enlarged veins in the stomach or esophagus of liver cancer patients. About 84 adults who recently had such bleeding controlled by standard endoscopy will be randomly assigned to recei…

This study tests whether adding a cancer vaccine (UCPVax) to standard immunotherapy (atezolizumab and bevacizumab) can shrink tumors better than standard therapy alone in people with advanced liver cancer that cannot be removed by surgery. About 105 adults who have not had prior …

This phase 2 trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus a targeted pill (TT-00420) in 100 people with advanced hepatocellular carcinoma that cannot be treated with local therapies. The main goal is to see how many patients' tumors shrink. Par…

This study tests a new drug called HLX13, which is a biosimilar (a very similar copy) of the approved immunotherapy YERVOY, in people with advanced liver cancer that cannot be removed by surgery. The trial will compare HLX13 to the original YERVOY, both given alongside another im…

This study tests whether taking prednisone, a steroid, before and during radiation therapy can protect the liver in people with liver cancer. About 20 participants will take prednisone for a short time around their radiation sessions. The goal is to see if it reduces liver inflam…

This phase 2 trial is testing whether a combination of two drugs, atezolizumab and bevacizumab, can safely treat liver cancer that has come back after a liver transplant. The study includes 50 patients who will receive the drug combo every three weeks along with a strict immunosu…

This study tests a new drug called AK112, alone or with other treatments, for people with advanced liver cancer that hasn't responded to standard care. The first part checks safety and the right dose, while the second part compares the new combinations to existing therapies. Abou…

This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy drugs (atezolizumab plus bevacizumab) can help people with advanced liver cancer that has spread into the main portal vein. About 40 participants will receive the combinatio…

This study tests two ways of injecting a dye (ICG) during laparoscopic liver surgery for people with liver cancer. The dye helps surgeons see tumor edges more clearly. Researchers want to know if injecting the dye into an artery works better than the usual method of injecting it …

This study tests a high-precision radiation treatment called SBRT for people with liver cancer who are waiting for a liver transplant but cannot have standard bridging treatments like radiofrequency ablation or chemoembolization. The goal is to see if SBRT can keep the cancer und…

This study tests whether adding nicardipine (a drug that blocks a cancer resistance protein) to standard chemoembolization (TACE) improves outcomes for people with liver cancer. About 152 adults with untreated liver tumors will be randomly assigned to receive either the standard …

This phase 2 trial is testing whether a combination of two immune-boosting drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to prior treatments. About 64 adults will receive the drugs by IV every three weeks. The main…

This phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in children and young adults up to age 30 with relapsed or hard-to-treat liver cancer. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Researchers will also study how the i…

This study tests histotripsy, a non-invasive treatment that uses focused ultrasound to destroy liver tumors without needles or surgery. It involves 40 adults with liver cancer who cannot have surgery or other standard treatments. The goal is to see if it is safe and effective at …

This early-phase study tests whether adding precise radiation (SBRT) to a standard two-drug combination (atezolizumab and bevacizumab) is safe and tolerable for people with advanced liver cancer that cannot be treated with surgery. The trial enrolls 18 participants and will also …

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests the safety of combining two drugs (atezolizumab and bevacizumab) with targeted radiation (SBRT) in 20 adults with liver cancer that cannot be surgically removed. The goal is to see if this triple therapy is tolerable and can help control the disease. Participants…

This Phase 3 trial tests whether giving a targeted chemotherapy treatment (TACE) after liver cancer surgery can prevent the cancer from coming back. It involves 442 patients with high-risk features for recurrence. Half will receive TACE, and the other half will have intensive mon…

This study tests whether adding a targeted chemotherapy procedure (TACE) to the drug lenvatinib works better than lenvatinib alone for people with liver cancer that cannot be removed by surgery. About 40 adults with early to advanced liver cancer will be enrolled. The goal is to …

This study tests whether a special nutritional drink taken for 7 days before liver surgery can improve recovery in 100 liver cancer patients. The drink contains ingredients like arginine and omega-3s that may support the immune system. Researchers will measure nutritional status,…

This study is testing a new way to deliver radiation therapy for liver cancer. Instead of multiple sessions over weeks, patients receive a single, high-dose treatment guided by real-time MRI scans. The approach aims to be more precise and convenient. The trial will enroll 62 adul…

This early-stage trial tests a single injection of MDN-001, which contains tiny radioactive beads (Yttrium-90), in 40 people with liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors, slow disease progression, and impro…

This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It will test if adding a procedure called TIPS (which places a small tube in the liver to improve blood flow) can help keep the liver working better for…

This trial tests whether adding liver-directed chemotherapy (GEMOX) to a two-drug immunotherapy regimen (durvalumab plus tremelimumab) improves outcomes for people with advanced liver cancer that has a high tumor burden. About 196 participants will be randomly assigned to receive…

This study combines a special type of radiation (PULSAR) with immunotherapy drugs to treat metastatic cancers in the abdomen and pelvis, including liver, kidney, and bladder cancers. About 103 participants will receive the treatment to see if it is safe and helps control the dise…

This study tests an experimental drug called GRWD5769, taken as a pill, for people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to check safety and find the right dose, and second, to see if the drug shrinks tumors wh…

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …

This early-phase trial is testing a new drug, BC2027, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow their growth. Participants re…

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

This early-phase trial is testing a new drug called CREPT-618 in 13 adults with advanced liver cancer who have not responded to standard treatments. The drug works by targeting a gene called CREPT, which may help control tumor growth. The main goals are to check safety, find the …

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This phase 2 trial is testing whether adding the immunotherapy drug tislelizumab after standard liver-directed treatments (like radiation) can help control inoperable liver cancer. About 35 adults with hepatocellular carcinoma who have not had systemic therapy will receive tislel…

This early study tests a new treatment called CG-102-12C for people with advanced liver cancer that has not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will e…

This early-phase study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to standard therapies. C-CAR031 uses a patient's own immune cells, modified to better target and attack cancer cells. The trial will enroll 72 participants to…

This study is testing a procedure called radiation segmentectomy for adults with liver cancer. Doctors deliver tiny radioactive resin beads directly to the tumor's blood supply to kill cancer cells while sparing healthy tissue. The goal is to find the best radiation dose for comp…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This study tests a new gel called INT001 that is injected directly into liver tumors to kill them. About 31 adults with liver cancer who cannot have surgery will receive one injection and be followed for 90 days. The goal is to see if the gel safely destroys the tumor and what si…

This early-phase trial tests a new treatment called TC-G203 for people with GPC3-positive solid tumors that have come back or spread after other treatments. The main goal is to find the safest dose and see if the therapy can shrink tumors. About 30 adults aged 18-75 who have not …

This study tests a new gel that hardens at body temperature to block blood flow to liver tumors during chemoembolization. About 216 adults with liver cancer will receive either the new gel or standard gelatin sponge particles. The goal is to see if the new gel better controls tum…

This phase 2 trial is testing whether giving two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—before surgery can help prevent liver cancer from coming back. The study includes 37 adults with resectable liver cancer that is beyond the Milan criteria, me…

This study tests a combination of an experimental immunotherapy (QL1706), a blood vessel blocker (bevacizumab), and chemotherapy given directly into the liver artery for people with advanced liver cancer that has caused a clot in the main portal vein. The goal is to see if this a…

This study tests whether giving a specific chemotherapy cocktail (mFOLFOX) directly into the liver artery after surgery can prevent liver cancer from coming back in patients at high risk. About 30 adults who had their liver cancer removed will receive up to two rounds of this inf…

This phase 2 trial tests whether a combination of radioactive beads (yttrium-90), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib) works better than standard chemoembolization for liver cancer that cannot be surgically removed. About 120 adults with non-met…

This phase 2 trial is testing whether a combination of Icaritin soft capsules and a liver-directed chemotherapy infusion (mFOLFOX) can prevent hepatocellular carcinoma from coming back after surgery in patients with high-risk features. About 30 participants will receive the treat…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to prior treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 plus standard care or a placebo plus…

This phase 2 trial tests a DNA vaccine called NWRD06 in 30 people with a specific type of liver cancer (GPC3-positive) who have had surgery to remove their tumors. The vaccine is given as a shot followed by a mild electric pulse to help it enter cells. The goal is to see if it ca…

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) in 32 people with advanced liver cancer who also have moderate cirrhosis (Child-Pugh B). The main goal is to see if the treatment is safe and tolerable, and to measure how well it shrinks tumo…

This study tests a new treatment called C-CAR031 for adults with advanced or recurrent liver cancer that has not responded to at least two prior therapies. C-CAR031 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells.…

This study tests an experimental drug called AST-3424 in people with advanced liver cancer that has a specific marker (AKR1C3-high) and has worsened after immunotherapy. About 75 participants will receive either AST-3424 or a standard drug (regorafenib) to see which helps them li…

This phase II study tests whether adding particle beam radiation therapy to standard immunotherapy can help people with advanced liver cancer that has spread into major blood vessels. About 128 adults with unresectable or metastatic hepatocellular carcinoma and vascular invasion …

This pilot study is testing whether combining stereotactic body radiation therapy (SBRT) with immunotherapy can shrink liver tumors that are too large or widespread to be surgically removed. The goal is to make these tumors operable, giving patients a chance at curative surgery. …

This early-phase trial tests a special radiation technique called vGRID SBRT for people with liver cancer that cannot be surgically removed. The main goal is to find the highest safe dose and check for side effects. Up to 18 adults with advanced or metastatic liver cancer will re…

This study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase t…

This early study tests whether giving focused radiation to a liver tumor a few weeks before surgery is safe and practical. The goal is to kill microscopic cancer cells around the tumor that often cause the cancer to return after surgery. Thirty patients with a single liver cancer…

This early-phase trial is testing a new drug called MT-303, alone or with two standard cancer drugs, in people with advanced liver cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see early signs of effectiveness. About 70 …

This study tests a new dye that makes liver cancer cells glow during surgery, helping doctors see exactly where the tumor is. About 30 adults with early-stage liver cancer will get the dye before their operation. The goal is to remove the cancer more completely and reduce the cha…

This study is for people with early-stage liver cancer who are scheduled for surgery. Researchers are testing whether an artificial intelligence (AI) tool can predict each patient's risk of the cancer returning. Patients identified as high-risk will receive a combination of chemo…

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery. Only people with high levels of the amino acid arginine in their blood can join. The goal is to see if the drug helps them live longer by breaki…

This early-stage trial tests a new drug called JMT106 in 200 people with advanced solid tumors, including lung and liver cancers, who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinkin…

This study tests a combination of two types of drugs (anti-PD-1/PD-L1 and anti-VEGF) in 50 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth. Participants will receive t…

This study tests whether adding chemotherapy to a two-drug combination (camrelizumab and apatinib) helps people with advanced liver cancer live longer without their disease getting worse. About 326 adults with liver cancer that cannot be removed by surgery will participate. The g…

This study tests whether giving the drug bevacizumab alone first, then adding atezolizumab later, works better than giving both drugs together from the start. It involves 20 adults with advanced liver cancer who also have fatty liver disease. The goal is to see if the sequential …

This early-stage trial is testing a new treatment called CNCT19 CAR-T cells for people with advanced liver cancer that cannot be removed by surgery or has come back after other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The main go…

This study tests whether treating donor livers with a special oxygen-rich cold fluid (HOPE) before transplant can help prevent liver cancer from returning. About 220 adults with liver cancer waiting for a transplant will be randomly assigned to receive either a standard preserved…

This phase II trial tests whether giving immune-boosting drugs (durvalumab with or without tremelimumab) after standard radiation can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation f…

This study tests a drug called cabozantinib in 20 adults whose liver cancer returned after a liver transplant. The goal is to see if the drug can control the cancer. Participants take the drug until it stops working or side effects become too bothersome.

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This early-phase trial is testing a new treatment for advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, which are genetically modified to recognize and attack cancer cells that produce a protein called AFP. Twelve…

This study tests two different ways to give chemotherapy combined with immunotherapy and a targeted drug for people with advanced liver cancer (BCLC stage C). One group gets standard IV chemo plus the drugs camrelizumab and apatinib. The other group gets the same drugs but with c…

This study tests a precise type of radiation called carbon ion radiotherapy for people with liver cancer that remains or comes back after a prior treatment (TARE). About 48 adults will receive this targeted radiation, with doctors tracking how well it shrinks tumors and whether s…

This phase 2 trial tests whether adding a temporary oil-based embolization (lipiodol) to standard chemotherapy infusion through the liver artery can shrink tumors better while keeping the liver healthy. The study enrolls 24 adults with advanced liver cancer that cannot be surgica…

This study looks at whether giving the drug tislelizumab at different infusion times after surgery can help prevent liver cancer from coming back in high-risk patients. About 33 adults aged 18-75 with early-stage liver cancer who had curative surgery will take part. The main goal…

This study tests whether adding a precise type of radiation (carbon ion radiotherapy) to standard immunotherapy drugs (atezolizumab and bevacizumab) can better control advanced liver cancer. About 52 adults with liver cancer that cannot be surgically removed will receive this com…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This phase 2 trial tests whether combining a liver-directed procedure (TACE) with two drugs—atezolizumab (immunotherapy) and bevacizumab (anti-angiogenic)—given before surgery can improve outcomes for patients with liver cancer at high risk of recurrence. About 30 adults with res…

This phase 2 trial tests whether combining dalpiciclib (a CDK4/6 inhibitor) with camrelizumab (an immunotherapy) can shrink tumors in 30 people with advanced liver cancer that progressed after prior immunotherapy. The study aims to find a new second-line option for this hard-to-t…

This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, for people with liver cancer (hepatocellular carcinoma) in Korea. About 246 patients who are already eligible for these drugs under Korean guidelines will be observed in real-world settings. The go…

This early-stage trial tests an oral tablet called BB102 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a specific protein (FGFR4) that may help control cancer growth. The study will check safety, side effects, and how the dr…

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors better in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and performanc…

This Phase 2 trial is testing whether a combination of three drugs—zanzalintinib, durvalumab, and tremelimumab—can shrink tumors in people with advanced liver cancer that cannot be removed surgically. The study will enroll 40 participants who have not received prior systemic ther…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This phase 2 trial is testing whether adding two drugs (atezolizumab and bevacizumab) after a targeted radiation treatment (SIRT-Y90) can help shrink tumors in people with advanced liver cancer that hasn't spread. About 100 participants will be randomly assigned to receive either…

This study tests a combination of three drugs (atezolizumab, bevacizumab, and memantine) in 19 adults with advanced liver cancer that cannot be removed by surgery. The main goal is to see how many patients have their tumors shrink or disappear. Participants must be newly diagnose…

This study tests a new approach for people with liver cancer that has spread to the portal vein (the main blood vessel to the liver). Participants will receive radiation therapy before surgery, along with two drugs (camrelizumab and apatinib) before and after surgery. The goal is…

This study tests whether taking atorvastatin (Lipitor) daily for 48 weeks can reduce the risk of liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants are randomly assigned to receive either the drug or a placebo. The main goal is to see if atorvastati…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This phase 2 trial tests a new combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs, tremelimumab and durvalumab. The goal is to see if this approach is safe and works bett…

This phase 2 trial tests whether giving a combination of targeted therapy (apatinib), immunotherapy (camrelizumab), and a procedure called TACE before surgery can help shrink centrally located liver tumors in people with stage B liver cancer. The goal is to make surgery more effe…

This early-phase trial is testing a new biologic drug called AWT020 in 60 adults with advanced solid tumors or lymphoma that have worsened after standard treatments. The main goals are to check the drug's safety at different doses and to see how the body processes it. Participant…

Researchers are testing whether advanced ultrasound techniques combined with machine learning can improve the detection and characterization of liver cancer compared to standard ultrasound. The study enrolls 200 adults who have a focal liver lesion visible on ultrasound or are in…

Researchers are studying whether a digital management platform can help diagnose liver cancer at an earlier stage in people with chronic liver disease. The study enrolls adults aged 18 to 75 with conditions such as chronic hepatitis B. The platform tracks patients and guides stan…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked. Researchers will compare the new CEUS criteria with standard CT or MRI scans in 200 adults. If accurate, this could make follow-up safer and easier by avoidin…

This study tests a special PET/CT scan using a radioactive tracer called PSMA to get clearer images of liver cancer (HCC). Researchers want to see if this dynamic whole-body scan can better detect new or returning tumors compared to standard methods. Forty adults with liver cance…

This trial tests a new radioactive tracer called 18F-X12 for PET/CT imaging in people with suspected or confirmed hepatocellular carcinoma, the most common type of liver cancer. The goal is to see if this tracer can accurately detect and stage tumors, and help spot recurrences af…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This trial is testing whether a special PET/CT scan using 18F-fluorocholine, along with a liquid biopsy, can predict how well patients with inoperable liver cancer (hepatocellular carcinoma) will respond to immunotherapy. The study enrolls adults with this type of liver cancer wh…

This pilot study explores whether a combination of advanced MRI scans and a blood test called HepQuant DuO can measure liver function in people receiving radiation therapy for liver cancer. The study will enroll about 40 adults with liver cancer or liver metastases. The goal is t…

This study is testing a new blood test designed to detect liver cancer (hepatocellular carcinoma) early in people who are at high risk because they have cirrhosis. The test looks for specific DNA markers and proteins in the blood that may signal the presence of cancer. Researcher…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study aims to develop a simple blood test that can tell the difference between two common types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal is to help …

This study compares two imaging methods—contrast-enhanced ultrasound and abbreviated MRI—to see which is better at detecting early-stage liver cancer (HCC) in people with suspicious but not yet cancerous liver nodules. Researchers will enroll 600 adults with cirrhosis and indeter…

This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve ear…

This study is testing whether adding a special PET scan (using F18-Piflufolastat) to standard imaging can better diagnose and stage liver cancer. Researchers will enroll 90 veterans with suspected or confirmed hepatocellular carcinoma. The goal is to see if the scan helps clarify…

This study tests whether a special type of CT scan (spectral CT) can better detect remaining liver cancer after a standard treatment called TACE. About 121 adults with liver cancer who have had TACE will get a spectral CT scan, and results will be compared to standard CT and to a…

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The…

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients a…

This study is testing whether proteins in the blood can help detect liver cancer at an early stage. Researchers will compare blood samples from 600 people—some with liver cancer and some healthy—to find protein patterns that signal the disease. The goal is to create a simple, non…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study tests whether an artificial intelligence (AI) model can help doctors more accurately stage and choose treatments for liver cancer (hepatocellular carcinoma). About 108 patients and doctors from different hospitals will participate. Doctors will make decisions with and …

This study is testing a blood test that looks for specific gene changes (methylation of GNB4 and Riplet genes) to see if it can detect when primary liver cancer comes back after treatment. The trial will follow 500 patients who had surgery, transplant, ablation, or chemoembolizat…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can predict if liver cancer will come back after surgery. Researchers will follow 255 patients for two years, taking blood samples regularly to see if the test detects recurrence earli…

This study tests whether a new type of ultrasound, called quantitative ultrasound (QUS), can find liver cancers that standard ultrasound often misses. About 328 adults at risk for liver cancer will receive both QUS and standard ultrasound, and results will be compared to MRI or b…

This study compares adding a quick MRI scan (fast-MRI) to standard ultrasound every six months for detecting early-stage liver cancer in people with cirrhosis who are at high risk. About 944 participants will be randomly assigned to either ultrasound alone or ultrasound plus fast…

This study tests whether a shorter, contrast-enhanced MRI scan can detect liver cancer recurrence as well as standard CT scans in people who have been cancer-free for over two years after treatment. About 455 participants will receive both scans to compare their accuracy. The goa…

This study tests whether a new type of PET scan that uses two different tracers at the same time can find and stage liver cancer and pancreatic neuroendocrine tumors better than standard single-tracer scans. Researchers will compare the number and location of tumors seen with the…

This study is testing a new AI-powered blood test that looks at platelets and immune cells to find early signs of eight different cancers, including lung, breast, and pancreatic cancer. Researchers will collect blood samples from 6,000 adults aged 40 and older, both with and with…

This study tests a new imaging tool that uses folic acid and carbon dots to make liver cancer cells glow. After surgery, the removed liver tissue is treated with these dots and scanned with a special camera. The goal is to see if this method can find cancer edges and tiny spots b…

This study is testing a blood test called Elecsys® GAAD to see if it can detect liver cancer earlier in people with liver cirrhosis. Current methods often find cancer too late, leaving few treatment options. The study will compare the GAAD test with standard care in 600 participa…

This study tests whether a 20-minute MRI scan without dye can detect liver cancer earlier than the usual ultrasound in 300 people with cirrhosis who are at high risk. Participants will get both scans every 6 months for 30 months. The goal is to see if the MRI catches cancers that…

This study is testing an artificial intelligence system that analyzes CT scans to predict microvascular invasion (MVI) in liver cancer patients. MVI is a key sign of aggressive cancer that currently can only be confirmed after surgery. The AI tool aims to give doctors this inform…

This study is testing a new blood test called delta-HLD to see if it can accurately detect liver cancer (hepatocellular carcinoma). Researchers will compare blood and tissue samples from 200 people, half with liver cancer and half with liver cirrhosis but no cancer. If the test w…

Researchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…

This study tests if a faster MRI scan, combined with a blood test, can find liver cancer earlier than the standard ultrasound in people with cirrhosis. The goal is to catch cancer at an early, more treatable stage and reduce deaths from liver cancer. About 4,700 veterans with cir…

This trial tests whether a different way of closing the abdominal wall during liver tumor surgery can lower the chance of developing an incisional hernia. 140 patients will be randomly assigned to receive either the new 'short stitch' method or the traditional closure. Researcher…

This study is testing whether offering a liver ultrasound and blood test every 6 months to people with cirrhosis can catch liver cancer early and reduce deaths. About 617 adults aged 40-79 with compensated cirrhosis (no severe complications) in one region of Denmark will be offer…

This study tests whether a green tea compound called EGCG can lower the risk of liver cancer in people with cirrhosis. Researchers will give EGCG or a placebo to 60 adults with cirrhosis and no history of liver cancer. The goal is to see if EGCG reduces a biomarker linked to canc…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study compares two types of nerve blocks (retrolaminar block vs subcostal TAP block) to control pain after open liver surgery for cancer. The goal is to see which block reduces the need for strong painkillers (opioids) and helps patients recover faster. About 90 adults under…

This study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests whether olanzapine, a drug already used for other conditions, can help cancer patients who are losing weight and appetite. About 66 adults with advanced lung, stomach, or bowel cancers will receive either olanzapine or a placebo. The goal is to see if olanzapine …

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests if applying a topical gel (indomethacin) to the hands before starting sorafenib can prevent or reduce hand-foot skin reactions, a common and painful side effect. About 39 adults with advanced liver cancer will use the gel twice daily for up to 12 weeks. The goal …

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This trial tests whether a smartphone app that tracks symptoms can improve quality of life for 500 liver cancer patients receiving immunotherapy. Patients in the intervention group report symptoms weekly via the app, which gives personalized advice and alerts doctors if scores ar…

This study tests whether a dietary supplement called β-alanine can reduce fatigue in people with advanced liver cancer who are receiving standard immunotherapy. About 158 participants will take either the supplement or a placebo alongside their regular treatment. The main goal is…

This study looks at whether two types of liver cancer treatments—procedures done by radiologists or targeted radiation—can improve quality of life for patients who cannot have surgery. About 78 adults with liver cancer will fill out questionnaires before and after treatment. The …

This study tests whether a mushroom extract called Antrodia cinnamomea can help liver cancer patients recover liver function and improve quality of life after a procedure called transcatheter arterial chemoembolization (TACE). Sixty adults with liver cancer will take either the s…

This study creates miniature, lab-grown versions of liver cancer tumors from patient biopsies. Researchers will test how well different treatments work on these models and look at how gut health and the tumor's environment affect the disease. The goal is to better understand live…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

Researchers at a single center are observing about 1,000 patients with hepatocellular carcinoma who receive systemic therapies. The study tracks overall survival, progression-free survival, and tumor response using standard imaging criteria. It also checks whether hepatitis C dru…

Researchers are observing people with small liver cancer, cirrhosis, and an overactive spleen who undergo laparoscopic liver surgery combined with spleen removal. The study enrolls 30 adults with low platelet counts and follows them for two years after surgery. It tracks changes …

This study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This pilot study compares two ways of collecting blood to detect circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is …

This study is observing 200 adults with advanced liver cancer who are starting a new treatment with two drugs, tremelimumab and durvalumab. Researchers want to see how long it takes for liver problems to get worse, how patients feel, and how safe the treatment is in everyday medi…

This study looks at whether measuring the liver's functional and total volume before treatment can help predict how well patients with advanced liver cancer respond to immunotherapy. Researchers will review imaging and clinical data from 467 patients who received immunotherapy fo…

This study aims to create patient-derived tumor models from 500 people with bladder, lung, stomach, or liver cancer, focusing on racial and ethnic minorities in California. By analyzing genetic and treatment response differences, researchers hope to guide more precise therapies f…

This study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…

This study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early…

This study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best tr…

This study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By …

This study follows 150 adults with liver or bile duct cancer who are receiving standard treatments like surgery, ablation, or chemotherapy. Researchers will collect repeated blood samples before, during, and after treatment to analyze tumor DNA, immune cells, and proteins. The go…

This study tests whether artificial intelligence can more accurately predict which patients on the liver transplant waiting list are at highest risk of dying or becoming too sick for surgery. Researchers will follow 630 adults with severe liver disease or liver cancer across five…

This European study is collecting health data from 4,500 adults listed for liver transplantation across 50 centers. The goal is to design and test new AI-based models that predict which patients are most likely to die or become too sick for transplant while waiting. If accurate, …

This study aims to find biological markers that can predict how well liver cancer patients respond to a combination of two immunotherapy drugs, tremelimumab and durvalumab. Researchers will follow 120 adults with advanced liver cancer who have not had prior systemic treatment. Th…

This international registry collects medical images and health data from people with liver cancer or liver metastases who received a procedure called combined portal and hepatic vein embolization (PVE/HVE). The procedure blocks two sets of veins in the liver to encourage the heal…

This study looks at whether CT scans can help doctors predict how well chemotherapy will work for people with pancreatic or liver cancer. About 259 adults with these cancers will get CT scans before and during treatment. The goal is to see if changes in the scan can tell if the t…

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard …

This study creates a registry of up to 4000 people with primary liver cancer (hepatocellular carcinoma or biliary tract cancer) treated at San Raffaele Hospital. Researchers will collect medical records and, for some participants, biological samples to search for new biomarkers t…

This study tests a program where patients with liver cancer meet with a navigator who helps them connect to medical and community resources. The goal is to understand patient needs and improve access to care and research participation. Adults with hepatocellular carcinoma or othe…

This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resis…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study is collecting blood, urine, and stool samples from 300 people with cirrhosis to build a biobank. Researchers will later use these samples to understand how factors like nutrition, physical activity, smoking, alcohol, and pollution influence the development of the most …

This study aims to build an AI model that uses medical images and tissue samples to predict which liver cancer patients will benefit from additional treatments after surgery. Researchers will analyze data from 11,000 patients to see if the AI's recommendations match real-world ou…

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid givi…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study aims to find tiny genetic markers (microRNAs) and blood chemicals that can tell doctors early whether a liver cancer patient will fully respond to heat-based tumor destruction. Researchers will analyze blood and tumor tissue samples from 150 adults with early-stage liv…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This study looks at how the autonomic nervous system (which controls automatic body functions) might be involved in liver cancer. Researchers will measure nerve activity and psychological traits in 100 adults with cirrhosis to find new ways to detect liver cancer earlier. The goa…

This study looks at whether the amount of healthy liver removed during surgery can predict liver failure afterward. Researchers will create a risk model based on 1,600 patients who had liver surgery for cancer. The goal is to help doctors identify high-risk patients before surger…

This study is recruiting 710 adults with fatty liver disease or alcohol-related liver disease, with or without cirrhosis, to understand why some develop liver cancer. Researchers will analyze genetic markers, immune factors, and imaging data from routine liver biopsies and blood …

This study looks at a method called 'Teaching the Teachers' to help spread liver cancer diagnosis guidelines. Experts learn the guidelines first, then teach other radiologists around the world. The goal is to see if this approach increases how often the guidelines are used. About…

This study aims to understand why many cancer patients lose muscle and fat (cachexia), a condition that worsens their health. Researchers will use advanced techniques to analyze samples from 1000 adults with certain cancers. The goal is to find early warning signs and new targets…

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…

This study looks at two types of surgery for pancreatic and liver tumors: open surgery and minimally invasive surgery. Researchers want to see which one leads to better survival, shorter hospital stays, fewer complications, and lower costs. The study will review records of 431 pa…

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…

This study is creating a registry for children and adults whose liver cancer (hepatoblastoma) has come back or not responded to treatment. Researchers will collect medical information, tumor samples, and scans from up to 500 participants to learn more about the disease. The goal …

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study explores whether using MRI scans before each radiation treatment is practical and helpful for people with liver or pancreatic cancer. About 30 participants will receive up to 5 extra MRIs alongside their standard radiation therapy. Researchers will measure patient sati…

This study looks at how pieces of tumor DNA circulating in the blood change in 15 liver cancer patients receiving a precise type of radiotherapy called SBRT. Researchers will take blood samples before, during, and up to 6 months after treatment to see if these DNA changes can hel…

This observational study follows 2000 adults with liver tumors who need surgery but have too little healthy liver left. Doctors use various techniques to make the liver grow before surgery. The study simply watches what happens in real practice—it does not test any new drug or tr…

This study looks at whether a patient's emotional state—like depression or anxiety—affects how well advanced liver cancer treatment works. Researchers will follow 90 people with liver cancer who are getting a combination of chemotherapy, targeted therapy, and immunotherapy. They …

This study looks at how liver cancer avoids being attacked by the immune system. Researchers will analyze tumor tissue and blood from 270 people with liver cancer to find specific molecules that help cancer hide. The goal is to better understand these escape mechanisms, which cou…

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This observational study is looking at whether certain substances in the blood can help predict and monitor how liver cancer responds to a treatment called TACE. Researchers will collect blood samples from 15 adult patients before and after TACE and compare them with standard ima…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can predict if liver cancer will come back after surgery. Researchers will take blood samples before and after surgery, then at 3 and 6 months, from 150 adults with liver cancer. The goal is …

This study looks at why some people are diagnosed with liver cancer at a late stage, when treatment is harder. Researchers will survey 730 patients in Los Angeles about social and economic challenges like transportation, food, and housing. They will also interview doctors and com…

This study is testing whether a special 3D ultrasound technique can help doctors better monitor how liver tumors respond to treatment. About 80 adults with liver cancer that started in the colon or rectum will be scanned before and during therapy. The goal is to see if this imagi…

This study looks back at 1,200 people who had a breathing tube placed during surgery to find out how often voice box injury happens and what makes it more likely. Researchers will check medical records and call patients to see if they had hoarseness or other throat problems after…

This study looks at whether repeated doses of a gadolinium-based contrast agent (a dye used in MRI scans) affect motor and cognitive functions in healthy adults. About 2076 participants will receive annual imaging and undergo tests over 5 years. The goal is to compare changes in …

This study looks back at the medical records of 2000 people with liver cancer in Guangxi, China. Researchers want to find out which treatments given before surgery (called conversion or neoadjuvant therapy) work best to help patients live longer. The study includes treatments lik…

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study is observing 84 adults with advanced liver cancer that cannot be removed by surgery. Researchers want to learn how the disease progresses, what treatments are used, and what side effects occur, especially in patients 65 and older. Participants will complete geriatric a…

This study looks at whether emotional disorders like depression and anxiety affect how well immunotherapy works in people with liver cancer. Researchers will follow 651 patients and compare treatment outcomes between those with and without emotional distress. The goal is to under…

This study is developing a computer-based planning tool to make transarterial radioembolization (TARE) more predictable for liver cancer patients. TARE delivers tiny radioactive beads directly to tumors, but results vary due to complex blood vessel patterns. Researchers will crea…

This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a type of internal radiation called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for tumor ce…

This study is testing two scoring methods (PLEASE and M10S20) to see if they can better predict serious liver events, liver cancer, and death in 600 people with advanced chronic liver disease. Participants are randomly assigned to standard care or a risk-based monitoring schedule…

This study looks at 600 adults with liver cirrhosis to see if a shorter MRI scan works better than ultrasound for finding early liver cancer. Researchers will also track body composition and other health changes over time. The goal is to improve how doctors monitor and predict li…

This study is for adults with advanced liver cancer who are starting a common immunotherapy combination (Atezolizumab and Bevacizumab). Researchers want to see if levels of a protein called Glypican-3 in the blood can help predict how well the treatment works. About 240 participa…

This study looks at blood samples from 20 people with advanced liver cancer who are starting immunotherapy. Researchers want to find genetic clues in immune cells that can tell if a patient will respond well to treatment. The goal is to better understand why some patients benefit…

This study looks at 1,000 people with alcohol-related liver disease to understand how their genes and drinking habits together raise the risk of liver cancer. Researchers will analyze DNA and lifestyle factors to create a risk score that could help doctors decide who needs regula…

This study looks at how the bacteria in your gut might influence diarrhea caused by cancer treatments. Researchers will follow 150 adults starting cancer therapy, collecting stool and blood samples to analyze gut microbiome changes. The goal is to better understand why some peopl…

This study aims to find genetic differences that make some people with fatty liver disease develop severe liver damage or cancer. Researchers will analyze DNA from 2880 adults, including those with advanced disease and healthy controls. The goal is to create better risk tests and…

This study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …

This study uses tiny, lab-grown liver models (organoids) made from patient cells to understand how a specific gene variant (I148M of PNPLA3) contributes to non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Researchers will expose these mini-livers to fatty acid…

This study looks at 300 liver cancer patients who cannot have surgery and instead receive a treatment called TACE. Researchers will use artificial intelligence to analyze routine CT scans taken before treatment, measuring body composition like muscle and fat. The goal is to creat…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…

This study is collecting blood and tumor samples from 50 people with advanced liver cancer who are receiving immunotherapy. Researchers will analyze the samples to find genetic and immune system markers that might predict how well the treatment works. The goal is to better unders…

This study will collect data from 1,500 people with liver tumors who are getting a procedure called thermal ablation, which uses heat to destroy tumors. Researchers will use artificial intelligence to analyze the data and find better ways to select patients, plan treatments, and …